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The risk of transmission of porcine microorganisms is, in addition to the immunological 20 
rejection and the physiological incompatibilities, a major hurdle to the clinical use of pig 21 
cells, tissues and organs for the treatment of organ failure in humans, to overcome the medical 22 
need caused by the increasing lack of human donors. Whereas most of the porcine 23 
microorganisms may be eliminated by early weaning, colostrum deviation, vaccination, 24 
antiviral drugs, animal isolation, Caesarean delivery of newborns, and embryo transfer, 25 
porcine endogenous retroviruses (PERVs) cannot be eliminated this way because they are 26 
integrated in the genome of all pigs [1]. Only a few years before evidence was published that 27 
PERV is able to infect human cells [2], two other retroviruses, simian immunodeficiency 28 
virus of chimpanzees (SIVcpz) and simian immunodeficiency virus from sooty mangabeys 29 
(SIVsm), now called human immunodeficiency viruses 1 and 2 (HIV-1 and 2), invaded the 30 
human population causing the fatal acquired immunodeficiency syndrome (AIDS) [3, 4]. 31 
Although HIV and PERVs are not very closely related, the fact that PERV is a retrovirus 32 
makes it so difficult to evaluate its risk [5]. Also, although most retroviruses are 33 
immunosuppressive in the infected host, the absence of an animal model makes it difficult to 34 
show this for PERV [6].   35 
 In recent years several strategies have been exploited to evaluate the risk posed by 36 
PERV, such as (i) infection experiments in vitro, (ii) infection experiments in vivo in small 37 
laboratory animals and in nonhuman primates (NHPs) with and without immunosuppression, 38 
(iii) preclinical trials in NHPs transplanting pig cells and organs with and without 39 
immunosuppression, and (iv) clinical trials mostly using encapsulated pig islet cells without 40 
immunosuppression. Despite these substantial efforts, these studies do not allow to make 41 
unequivocal conclusions whether PERVs pose a risk in the case of treatment of humans with 42 
porcine cells, tissues or solid organs, as will be discussed in the sections below. 43 
Unfortunately, there are no alternative approaches to test this in an experimental setting: 44 
essentially clinical trials are needed to answer this question. 45 
1. Infection experiments in vitro 46 
There are three types of PERV, PERV-A and PERV-B which are present in the genome of all 47 
cells and which infect human cells (human-tropic viruses), and PERV-C which is present in 48 
most, but not all pigs and infects only pig cells (ecotropic virus) (for review see [1]). This 49 
means that PERV-A and PERV-B are able to infect different human cells and cell lines in 50 
vitro, in cell culture [2]. Recombinant viruses between PERV-A and PERV-C (PERV-A/C), 51 
able to infect human cells and characterized by a high replication rate, been have described 52 
[1]. Some human cell lines such as the 293 pig embryonic kidney cell line are highly 53 
susceptible, and after repeated passages of PERV through these human cells, the virus showed 54 
a higher replication rate and genetic changes in its long-terminal repeat (LTR). These viruses 55 
were called “human cell-adapted PERVs” [7]. The lack of the restriction factor apolipoprotein 56 
B-editing catalytic polypeptide-like subunit (APOBEC) and transformation by DNA viruses 57 
are thought to be the reason for the high susceptibility of 293 cells. However, primary cells 58 
including porcine aortic endothelial cells (PAEC) and peripheral blood mononuclear cells 59 
(PBMCs) have also been infected [8, 9]. PBMCs can more effectively be infected with human 60 
cell-adapted PERVs, however it remains unclear whether the virus infection is productive, 61 
e.g., whether the virus infects cells and produces excess progeny [10]. In the case of PAEC, a 62 
productive infection including mRNA production and particle release have been demonstrated 63 
[8]. Güell et al. [11] described the infection of human umbilical vein endothelial cells 64 
(HUVECs) with PERV, and the presence of proviral DNA in the infected cells. However it 65 
was not clear how the HUVECs had been derived and whether the infection was productive. 66 
Furthermore, all infection experiments, including the experiment with HUVECs, have been 67 
performed using PK15 cells or heavily infected 293 cells as virus source, both releasing high 68 
amounts of virus. In contrast, most primary pig cells, for example pig PBMCs, show only a 69 
low PERV expression at the RNA level and no virus release [12]. Only after mitogenic 70 
stimulation of some pig PBMCs, virus particles were released that were able to infect human 71 
293 cells [12, 13]. Therefore, these in vitro studies have only a limited relevance for the 72 
evaluation whether PERVs pose a risk for xenotransplantation (Table 1).  73 
 74 
2. Infection experiments in vivo  75 
PERV-A and PERV-B infect not only human cells in vitro, but also cells of other species 76 
(polytropic viruses), with some exceptions such as mouse cells [1, 14-18]. Based on these 77 
results numerous attempts have been undertaken to establish a small laboratory animal model 78 
of PERV infection (Table 1). However, injection of PERV preparations into mice, rats, guinea 79 
pigs, and minks, with or without immunosuppression, failed to infect these animals [15-19]. 80 
Cells from NHPs could also be infected in vitro, however in most cases this did not result in a 81 
productive infection [17, 19]. In some cases, e.g., chimpanzee cells, only human cell-adapted 82 
PERVs were able to show infection [20]. When three NHP species, namely baboons, rhesus 83 
monkeys and pig-tailed monkeys, were inoculated with human cell-adapted PERV-A/C, and 84 
the animals were treated daily with three different immunosuppressive drugs (cyclosporine, 85 
everolimus (RAD), and methylprednisolone), no PERV infection was observed during a 86 
follow-up of more than 300 days [17, 21].  87 
 Inoculation of rats with PERV or PERV-producing cells [22], or pig islet cells [16], as 88 
well as treatment of minks [18] or guinea pigs [22] with PERV did not result in infection. 89 
Only in guinea pigs a transient infection was observed [23]. Mice could not be infected [15, 90 
24], because mice lack a PERV receptor [25]. Noteworthy, early reports on PERV infection of 91 
SCID mice [26, 27] and athymic mice [28] proved to represent an artifact based on 92 
pseudotyping with endogenous murine retroviruses [29, 30]. Mice transgenic for the human 93 
PERV receptor huPAR-2 have been generated, and it was reported that they could be infected 94 
with PERV in vivo [31]. Although this is the only known in vivo model of PERV infection, no 95 
follow-up studies on pathogenic effects of the virus were published.  96 
 In rhesus and cynomolgus macaques, and baboons, the main virus receptor PAR-1 was 97 
found to be genetically deficient by a mutation at the same position as reported in mice, which 98 
is one explanation for the inefficient infection [32]. The receptor in African green monkeys 99 
does not have this mutation, but nevertheless the replication is quite low [32]. 100 
 To summarize, all small laboratory animal and NHP model systems are not suitable to 101 
evaluate the risk posed by PERVs or to study PERV pathogenesis (Table 1). 102 
 103 
3. Preclinical trials in NHPs 104 
In recent years a number of pig-to-NHP preclinical xenotransplantation studies have been 105 
performed regarding hearts, kidneys, islet cells, or studies performing perfusion of pig liver, 106 
under immunosuppression (for review see [1]). In all these studies, and also in more recent 107 
transplantations not listed in [1], i.e., studies on islet cell transplantation in marmosets [33] 108 
and cynomolgus monkeys [34], no PERV transmission was observed. However, since the 109 
PERV receptor in NHPs is not functional, these results cannot be used to evaluate the safety 110 
of xenotransplantation using pig cells and organs (Table 1). Hence, it does not make sense to 111 
include the monitoring for PERV transmission in pivotal nonclinical trials before phase 112 
transition to clinical development. Interestingly, some regulatory agencies require such 113 




4. Clinical trials 118 
In the past, more than 200 humans have received a xenotransplantation product comprising 119 
pig cells or tissues including ex vivo perfusion of pig organs or pig-cell based bioreactors ([35, 120 
36], reviewed in [1] and [37]. No evidence for virus transmission was obtained using sensitive 121 
PCR-based methods and immunological assays for the detection of antiviral antibodies. 122 
Neither antibodies against PERV as an indirect sign of infection, nor provirus integration in 123 
PBMCs of the patients was observed.  124 
 During the last years further clinical trials have been performed, including the first 125 
prospective clinical trials under proper regulatory oversight using encapsulated pig islet cells 126 
to treat type one-diabetes in New Zealand [38] and Argentina [39]. Although the clinical 127 
efficacy in these trials was limited, no PERV transmission has been observed [40, 41].  128 
 In all of these porcine islet clinical trials no immunosuppression was given and the islet 129 
cells were transplanted encapsulated in biopolymers, a procedure which protects from host´s 130 
humoral and cellular immune system (immunoglobulins and immune cells), but also which 131 
prevents release of PERVs (Table 1). After some pioneering explorations more than 40 years 132 
ago, transplantation of a large vascularized organ accompanied by an effective pharmaceutical 133 
immunosuppression has still not been performed. 134 
 135 
5. Perspectives 136 
 Although human cells can be infected with PERVs under specific and somewhat 137 
artificial conditions, i.e., co-culture of human cells with porcine cell lines that do not resemble 138 
primary pig cells regarding PERV expression and virus production, or co-culture of porcine 139 
cells which human target cell lines that do not resemble primary human cells, no PERV 140 
transmission has been observed in the first clinical trials. Also, upon inoculations of PERV 141 
particles or PERV-producing cells into small laboratory animals or NHPs, no PERV 142 
transmission has been observed. In addition, no PERV transmission was observed in 143 
preclinical trials transplanting encapsulated pig islets in diabetic NHPs or transplanting 144 
kidneys or hearts into immunosuppressed NHPs. Noteworthy, the trials and infection 145 
experiments in NHPs are limited by the lack of a functional PERV receptor in NHPs. Trials in 146 
humans used mainly encapsulated pig islet cells. Encapsulation prevents immune rejection, 147 
but could also prevent the release of PERV and other pathogens. Ex vivo perfusion of pig liver 148 
and spleen by human blood, pig skin transplantations, and injection of pig neuronal cells into 149 
the immunoprotected human brain, have also been performed [35, 36]; but till now 150 
transplantations of vascularized pig organs under chronic immunosuppression have not been 151 
performed. At present there are no additional experimental approaches available to evaluate 152 
whether PERVs pose a risk. 153 
 During the last years, first reports have been published that PERVs in the genome can 154 
be inactivated by CRISPR/Cas9-mediated gene editing tools [42], and also that this procedure 155 
allows the generation of live pigs with all PERVs being inactivated [43]. Although the 156 
functionality has been shown in in vitro cell culture, with inherent low translation value to the 157 
pig-to-human clinical situation as outlined above, it needs to be shown in an in vivo situation 158 
that the inactivation of PERVs in the pig donor makes sense, also in relation to the off-target 159 
effects of the gene editing procedure [44]. 160 
This aside, the possibility of gene editing resulting in inactivated PERVs raised the question 161 
whether conventional pigs can still be used for xenotransplantation, or whether only 162 
CRISPR/Cas9-inactivated pigs have to be used as source animals for future 163 
xenotransplantations [11, 44-46]. PERV proviruses inactivated by CRISPR/Cas9 cannot be 164 
restored by recombination, since in all proviruses the gene coding for the important reverse 165 
transcriptase is destroyed. Recombination or co-packaging between PERVs and human 166 
endogenous retroviruses (HERVs) have not been reported [47]. Furthermore, off-target effects 167 
by CRISPR/Cas9 may happen, but they will be detected when analyzing the health of the 168 
animals, and animals with defects will be eliminated. 169 
 Therefore, two options for the first solid organ xenotransplantations could be foreseen. 170 
First, the use of organs from conventional, non-CRISPR/Cas9-treated animals in well-171 
controlled trials, e.g., using pigs with absence of PERV-C, low copy number and low 172 
expression of PERV-A and PERV-B. Monitoring of the xenotransplant recipient would be as 173 
proposed by regulatory agencies [48] using highly sensitive PCR-based and immunological 174 
methods. Alternatively, pigs with CRISPR/Cas9-inactivated PERVs could be used. The 175 
monitoring might in first instance be similar as mentioned above, considering that the sense of 176 
the gene editing can not be demonstrated in in vivo animal models [44]. Additional strategies 177 
to prevent PERV transmission have been considered such as a vaccine based on neutralizing 178 
antibodies [49-52] and antiretroviral drugs (for review see [53]), which may be used should a 179 
positive detection of PERV occur. With this in mind, it seems feasible to go ahead with 180 
conventional animals as has been done in many trials before. 181 
 182 
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Table 1 Evaluation of the results of different PERV transmission experiments 










pig islet and other 
cells to humans, ex 




low number, no 
immunosuppression 
 No relevance for 
solid organ 
transplantation 
into humans  
Preclinical 
transplantation of 
different pig organs 
into non-human 
primates 
No transmission Absence of 
functional PERV 
receptor  





experiments in vivo 
in small animals and 
non-human 










receptor, or low 
PERV receptor 
density  





experiments in vitro  
Infection of 
human cells and 
cells from other 
species 
 Use of high 
virus load for 
infection, target 
cells susceptible 
due to lack of 
restriction 
factors, use of 
human cell 









* In some patients microchimerism was detected, e.g., the presence of pig cells, but no infection 
[35]. 
**Reports showing that SCID mice were infected with PERV [26-28] were the result of an artefact 
based on pseudotyping between PERV and endogenous murine retroviruses [29, 30]. 
 
 
